Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 7281 - 7288 of 12143 results
Supreme Court Shuts the Door on Patent Laches
March 21, 2017| Blog| Viewpoint
New York Medical Society Warns Providers to Avoid Percentage-Based Fees
March 21, 2017| Blog| Viewpoint
Wyden’s C-THRU Act – Publicizing PBM Rebate Data
March 21, 2017| Blog| Viewpoint
An Arbitration Agreement That Attempts to Skew a Statutory Arbitration Scheme Is Void as Against Public Policy
March 20, 2017| Blog| Viewpoint
Upcoming Webinar: AEE’s State of Advanced Energy: Markets, Trends, Jobs (March 30)
March 20, 2017| Blog| Viewpoint
More Broken Privacy Promises from Upromise: Key Takeaways From Upromise’s Latest Settlement with the FTC
March 20, 2017| Blog| Viewpoint
BPCIA Helps Amgen Gain Dismissal of Genentech Complaint
March 20, 2017| Blog| Viewpoint
Federal Circuit Reverses PTAB’s Holding of Anticipation Despite an Element Missing from the Prior Art
March 20, 2017| Blog| Viewpoint
News & Press Releases
Mintz Advises Point72 and Tsunami Express Car Wash in Acquisition of 53 Car Wash Locations from Whistle Express Car Wash
September 16, 2025
Mintz advised Point72 and Tsunami Express Car Wash, its portfolio company, in Tsunami’s acquisition of 53 car wash locations from Whistle Express Car Wash, which is owned by affiliates of Oaktree Capital Management.
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Events
Podcasts
Mintz On Air: Practical Policies – DEI Developments: The Proxy Problem
September 16, 2025| Podcast|
Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|